Serotonin receptors and heart valve disease--it was meant 2B. - Wikidata - wikimedia - TriplyDB

Serotonin receptors and heart valve disease--it was meant 2B.

Serotonin receptors and heart valve disease--it was meant 2B.

http://www.wikidata.org/entity/Q34173511

about

Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders Creation of a free, Internet-accessible database: the Multiple Target Ligand Database Complications from carcinoid syndrome: review of the current evidence (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling Monoamine oxidases as sources of oxidants in the heart Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.Potential drug targets for calcific aortic valve disease.The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.Directing valvular interstitial cell myofibroblast-like differentiation in a hybrid hydrogel platform.Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality.Microarray analyses to quantify advantages of 2D and 3D hydrogel culture systems in maintaining the native valvular interstitial cell phenotype.Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations.Lorcaserin Reduces the Discriminative Stimulus and Reinforcing Effects of Cocaine in Rhesus Monkeys.Mechanisms of calcification in aortic valve disease: role of mechanokinetics and mechanodynamics Acute pergolide exposure stiffens engineered valve interstitial cell tissues and reduces contractility in vitro.Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments.Serotonin paracrine signaling in tissue fibrosis Current concepts in diagnosis and perioperative management of carcinoid heart disease.Distinct signaling pathways activated by "extracellular" and "intracellular" serotonin in heart valve development and disease.Aryl biphenyl-3-ylmethylpiperazines as 5-HT7 receptor antagonists.Serotonin and catecholamines in the development and progression of heart valve diseases.Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the 'Working Group on myocardial and pericardial diseases' of the European Society of Cardiology Endorsed by the Indian Academy of Echoc In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.Sub-aortic obstruction of left ventricular outflow tract secondary to benfluorex-induced endocardial fibrosis.Atypical sympathomimetic drug lerimazoline mediates contractile effects in rat aorta predominantly by 5-HT2A receptors.Multiple serotonergic paths to antidepressant efficacy.Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.Neuroendocrine tumors and fibrosis: An unsolved mystery?Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products.Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis.MTLD, a Database of Multiple Target Ligands, the Updated Version.Elevated Serotonin Interacts with Angiotensin-II to Result in Altered Valve Interstitial Cell Contractility and Remodeling.Echocardiography in functional midgut neuroendocrine tumors: When and how often.Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain.ToxCast: Predicting Toxicity Potential Through High-Throughput Bioactivity Profiling

P2860

Q26748728-C052FF83-D6E4-4BC4-9224-B1390CDD25BC Q27902291-F5AA65E0-9475-4419-AA24-CC99373E9062 Q28068096-46AEA3E0-38BA-45CC-93DD-2866AF879AB4 Q28248215-EF255EC5-1ADC-4A42-88A6-3DA38D7FCCFD Q33723676-E48F8FCF-1D29-4926-BC8B-93D75BE05386 Q34332000-08E0A2AA-490E-45A2-B1A4-8DF23875A1C5 Q34399089-CBC8DC33-18B8-4364-A24A-F500A16A16F8 Q34546304-2CAB40FD-6446-467D-AC5F-AED64DB17955 Q34772618-BC764A74-8ACD-4EED-980D-5DEF2386332A Q35049574-997CB162-8B0E-43FC-AF4D-CEFA5E152DDF Q35678070-3129FEB3-5FCD-42CA-B56B-82A93392C5C1 Q36322429-95CFD3A4-D859-49B9-AF34-57E11BD83B38 Q36350604-88B6939A-43FF-47EA-9D16-C94D3C5E4466 Q36432310-5DE73BBE-0E8C-4D8A-96FE-C93F3768E0C9 Q36857772-7D2414CF-2717-49B0-BDA1-854F22A8CCD2 Q36993985-4F45E738-720E-4558-9F68-1F15132CE8EF Q37125668-44168668-15CA-4AFD-B3D5-87E95BAD1D49 Q38034731-8D15A975-3FD1-43F1-923B-C0E8BD2C8C99 Q38049023-8570C0FE-A678-43B5-9FB9-7A9CAE1612F2 Q38061530-4D483D4A-0A1E-475D-A99A-6BE4D0E6D38E Q38100690-FA9ED852-877F-4105-8011-B39CA1E6D342 Q38446875-6F8EC281-3F11-4043-BFEB-59079815D7CA Q38634250-F5F72919-9A42-4E62-BECE-0AABB9797A71 Q38762256-45605CBC-19AB-46F7-A2FA-B77F6DC7FB68 Q38782767-7E64FB69-62C2-4BAA-AE83-A4411BDE5A51 Q39369233-FEA678AF-52F6-455A-8277-A35A358077E0 Q40963514-907D2395-4775-48D9-911C-486CE9D257C8 Q41598101-D7346108-7FB3-4D6C-A478-73FD372C9DDF Q43573466-D21E3905-D0DF-4DD1-B7B7-2D8CC99F3AF2 Q47588598-72140467-F009-4290-91D9-6849BA374081 Q47639140-11E61B1E-A255-4346-A939-8793CE22F427 Q47677518-207B35CD-4FAE-4509-B1EB-A720D7B53AA0 Q47720153-BDB49577-8574-4909-99D7-BD7260D86709 Q48026143-7746BC2A-D821-4625-BCFA-DB012B138010 Q49026083-930D338C-4A5E-44E2-BE47-A94769A8ED9F Q50212515-20F91358-5A60-42E8-A34D-8318483B2EC8 Q50214900-2E8C1A7D-76A0-4959-998D-0FA38FD6D0D0 Q52865572-3DD27D17-1E53-49B4-B0A6-B573EE9F9A05 Q55711478-5271AD85-4B5D-40DB-8B4E-A89540528A7B Q57018719-759A7D35-5B78-4AF3-A781-F0146D3CC5FB

P2860

Serotonin receptors and heart valve disease--it was meant 2B.

http://www.wikidata.org/entity/Q34173511

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Serotonin receptors and heart valve disease--it was meant 2B.

@ast

Serotonin receptors and heart valve disease--it was meant 2B.

@en

Serotonin receptors and heart valve disease--it was meant 2B.

@nl

type

label

Serotonin receptors and heart valve disease--it was meant 2B.

@ast

Serotonin receptors and heart valve disease--it was meant 2B.

@en

Serotonin receptors and heart valve disease--it was meant 2B.

@nl

prefLabel

Serotonin receptors and heart valve disease--it was meant 2B.

@ast

Serotonin receptors and heart valve disease--it was meant 2B.

@en

Serotonin receptors and heart valve disease--it was meant 2B.

@nl

P1433

Q34173511-CDBB8D76-546B-48BC-9CE5-071218D31C6F

P1476

Q34173511-CA0EE5C7-A0D3-4707-96BA-F51307BE4110

P2093

Q34173511-6763EB75-0BD6-47E4-84F5-66B727CA5A3C

Q34173511-7148B04C-5565-4262-BE35-0168EE02B94A

Q34173511-8E0643B2-8103-4828-8A1C-246FDCC5AB00

Q34173511-F3B74A8B-20BE-4CE8-8D4E-AB0C39D6BA19

P2860

Q34173511-00A5582C-6A4E-4530-9E9B-092D98113136

Q34173511-03E0960B-CB83-41A5-AAC6-8F00B35D9009

Q34173511-077A4E2B-7BC7-4C13-A561-35F8FC0DD96F

Q34173511-0A67051B-25B9-409F-A0EA-085B6AA0EF45

Q34173511-0C797A41-ACE5-408E-AA53-5B209F8DD465

Q34173511-107E0316-CD90-448D-8608-BCB8A3B00C02

Q34173511-182C3E43-2A42-4821-AC36-C265F35EE802

Q34173511-19E42D6D-9DAE-4248-9440-4D238D660997

Q34173511-1AC50B79-FC0F-4131-A28A-22D930CA8414

Q34173511-1BD5FE82-5551-4EED-B111-AE6233638713

P304

Q34173511-5CA7467F-1207-4E35-B8E9-035F8D6F8C00

P31

Q34173511-9912C2F3-00CE-4140-92C8-40762D2B2F1C

P356

Q34173511-4834EF5E-2696-4E96-8D51-3968E80E375B

P433

Q34173511-3537F409-B763-4509-9DCC-44CF63E7F062

P478

Q34173511-D2D149F6-4F20-455B-A828-E21138695BBF

P577

Q34173511-43560C77-E222-4EC7-A250-DCD04DCCC6C3

P5875

Q34173511-056EA4D6-F1CD-4277-B6A9-1D051B24ED6C

P698

Q34173511-B3C0E3F2-B38D-478D-9484-3F93209D3218

P921

Q34173511-5527b513-8226-49d9-a88e-684e15775d7d

P932

Q34173511-109123C6-A8A8-43E9-8BFC-DBEB32F81667

P356

J.PHARMTHERA.2011.03.008

P1433

Pharmacology & Therapeutics

P1476

Serotonin receptors and heart valve disease--it was meant 2B.

@en

P2093

Bryan L Roth

http://www.w3.org/2001/XMLSchema#string

Joshua D Hutcheson

http://www.w3.org/2001/XMLSchema#string

Vincent Setola

http://www.w3.org/2001/XMLSchema#string

W David Merryman

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor

Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix

Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor

Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine

P304

146-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHARMTHERA.2011.03.008

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50866483

http://www.w3.org/2001/XMLSchema#string

P698

21440001

http://www.w3.org/2001/XMLSchema#string

P921

P932

3179857

http://www.w3.org/2001/XMLSchema#string